Antisense Pharma releases trabedersen Phase I/II trial results
AP 12009-P001 Phase I/II trial is investigating the safety and tolerability of i.v. administration of trabedersen in 61 patients with advanced solid tumors known to overproduce TGF-b2, who
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.